表紙:デジタル療法の世界市場
市場調査レポート
商品コード
903083

デジタル療法の世界市場

Digital Therapeutics

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 202 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.34円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

デジタル療法の世界市場
出版日: 2022年01月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 202 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界のデジタル療法市場を調査し、市場の概要、セグメント・地域別の市場規模の推移と予測、市場動向および成長要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 注目企業
  • 市場動向と成長要因
  • 世界市場の見通し

第3章 市場分析

  • 地域市場の分析
  • 米国
    • 概要
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • その他の欧州諸国
  • アジア太平洋地域
  • その他の地域

第4章 競合情勢

  • 2MORROW, INC.
  • CANARY HEALTH
  • GINGER.IO
  • LIVONGO HEALTH
  • MANGO HEALTH
  • NOOM INC.
  • OMADA HEALTH, INC.
  • PROPELLER HEALTH
  • PROTEUS DIGITAL HEALTH, INC.
  • WELLDOC

第5章 調査資料

目次
Product Code: MCP11567

Abstract:

Global Digital Therapeutics Market to Reach US$12.1 Billion by the Year 2026

Digital therapeutics (DTx), an emerging trend in the rapidly growing mobile health (mHealth) space comprises software programs that blend medical intervention with digital platforms for treatment of medical disorder or conditions. Digital therapeutics enables improved health monitoring, prevention and management leading to improved health outcomes and reduced healthcare expenditure. With rising penetration of smartphones and internet usage, digital therapeutics can offer basic medical guidance, work in combination with drug regimens, use cognitive stimulation to induce behavioural changes, connect with wearables and medical equipment through the use of mobile apps. Rising incidences of chronic diseases, growing geriatric population, technological advancements, benefits of digital therapeutics, and pressing need to curb rising healthcare costs are key growth drivers spurring significant growth in the global market. Strong adoption of digital platforms like smartphones, apps, electronic wearables, mobile internet; growing focus on value based care; and rising venture capital investments in digital health based business models spur growth in the market. The momentum is likely to accelerate further with advent of next-generation technologies such as IoT and Artificial Intelligence (AI), as these `high-tech` modalities hold immense potential to augment roll out of DTx interventions as a complementary product or as a complete replacement to traditional therapeutics.

Amid the COVID-19 crisis, the global market for Digital Therapeutics estimated at US$2.6 Billion in the year 2020, is projected to reach a revised size of US$12.1 Billion by 2026, growing at a CAGR of 27.7% over the analysis period. B2B, one of the segments analyzed in the report, is projected to grow at a 28.8% CAGR to reach US$13.3 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the B2C segment is readjusted to a revised 19.2% CAGR for the next 7-year period. This segment currently accounts for a 12.9% share of the global Digital Therapeutics market.

The U.S. Market is Estimated at $1.4 Billion in 2021, While China is Forecast to Reach $909.2 Million by 2026

The Digital Therapeutics market in the U.S. is estimated at US$1.4 Billion in the year 2021. The country currently accounts for a 41.8% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$909.2 Million in the year 2026 trailing a CAGR of 28.9% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 23.8% and 22.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 27% CAGR while Rest of European market (as defined in the study) will reach US$1.2 Billion by the end of the analysis period. The United States and Europe represent key markets, led supported by well-developed digital infrastructure that provides the foundation for DTx. In Asia-Pacific region, growth is driven by rising prevalence of chronic illnesses and growing geriatric population.

Select Competitors (Total 108 Featured) -

  • Canary Health, Inc.
  • Dthera Sciences
  • Fitbit Health Solutions
  • Livongo Health, Inc.
  • Medtronic, Plc
  • Omada Health, Inc.
  • Propeller Health
  • Pear Therapeutics, Inc.
  • Proteus Digital Health, Inc.
  • WellDoc, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • 2020: A Year of Disruption & Transformation
    • As the Race between the Virus & Vaccines Intensifies, Review of the World Economy in 2021
    • EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
    • COVID-19 Pandemic Expedites Implementation of Digital Therapeutics
    • Prominent Drivers Enabling Digital Therapeutics Market to Leapfrog
    • Digital Therapeutics: An Introduction
    • EXHIBIT 2: Digital Therapeutics Market by Disease Condition: 2021E
    • Outlook
    • Strategies to Push Uptake of Digital Therapeutics
    • Leading Markets
    • Factors Impeding Growth
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Digital Therapeutics Continue to Attract Venture Capital Investments
    • EXHIBIT 3: Digital Health Funding by Segment (in US$ Million): 2020
    • EXHIBIT 4: Top Funded Clinical Indications: 2020
    • EXHIBIT 5: Top Funded Clinical Indications: Q1-Q3 2021
    • EXHIBIT 6: Digital Therapeutics Funding in US$ Million: 2018-2021 9 Months
    • EXHIBIT 7: Digital Therapeutics Deal Count: 2018-2021 9 Months
    • Startups Flock the Digital Therapeutics Market
    • Select Digital Therapeutics Startups
    • EXHIBIT 8: Quarterly Investments by Digital Therapeutics Startups in US$ Million: Q1 2020 to Q3 2021
    • EXHIBIT 9: Top 10 Equity Deals in Q3'21
    • Pipeline Products Drive Growth Prospects
    • Select FDA Approved DTx
    • A Snapshot of Select DTx Pipeline Products
    • Artificial Intelligence to Play a Significant Role in Improving Clinical Outcomes
    • EXHIBIT 10: Global Healthcare Artificial Intelligence Market by Application: 2021
    • Why Healthcare & Pharmaceuticals are joining the Digital Therapeutics Bandwagon?
    • Pharma Majors Foray into Uncharted Territory
    • Pharmaceutical Companies Team Up with Payers to Seek Reimbursement
    • Growing Need to Break the Stigma Associated with Mental Health Augurs well for Digital Therapeutics
    • Select Mental Health Stats Worldwide
    • Potential Areas for Digital Therapeutics
    • EXHIBIT 11: Global Number of People Suffering from Mental Disorders (In Million)
    • Pandemic Pulls up Lever for Digital Mental Healthcare
    • EXHIBIT 12: Anxiety and Depression on Rise Amid the Pandemic: Percentage of US Adults Displaying Symptoms of Anxiety and Depressive Disorder (Jan-June 2019, May 2020, and December 2020)
    • High Prevalence of Chronic Diseases and Growing Focus on Preventative Healthcare Widens Growth Opportunities
    • Role of Digital Therapeutics in Type 2 Diabetes Reversal
    • EXHIBIT 13: World Diabetes and Population Statistics (2019, 2030 & 2045)
    • EXHIBIT 14: World Diabetes Prevalence: 2000-2019, 2030 and 2045
    • Growing Overweight and Obese Population Benefit Market Prospects
    • EXHIBIT 15: Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely Obese Adults for 2014 & 2025
    • EXHIBIT 16: COVID-19 Pandemic Adds to the Healthcare Burden of Nations Worldwide: Obesity-Related Health Spending as % of Total Health Expenditure for the Period 2020-2050
    • Managing Heart Failure through Digital Interventions
    • EXHIBIT 17: Global Annual Medical Cost of CVD in US$ Billion (2010-2030)
    • Neurological Conditions
    • EXHIBIT 18: Chronic Disease Management in Developed Countries (2019): Percentage Distribution of Patient Population by Chronic Disease Type in the US, Germany, and UK
    • How Digital Therapeutics is Changing Oncology Care Landscape?
    • EXHIBIT 19: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Data Generation for Drug Development
    • Proliferation of Smart Devices Bodes Well for Market Growth
    • EXHIBIT 20: Smartphone Adoption as Share of Total Population: 2016-2021
    • Mobile Healthcare Gains Momentum amid the Pandemic
    • EXHIBIT 21: Global Smartphone Shipments in Million Units: 2010-2021
    • Delivery through Wearable Devices Holds Strong Potential
    • EXHIBIT 22: Global Wearable Device Shipments in Million Units for the Years 2017, 2019, 2021, 2023, and 2025
    • Growing Focus on Reducing Healthcare Costs Bolsters Market Growth
    • EXHIBIT 23: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Digital Therapeutics Evolves as a Viable Solution for Medication Adherence
    • Aging Population and their Vulnerability to Various Health Conditions: A Vital Growth Driver
    • EXHIBIT 24: Global Population for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Digital Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for Digital Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027
    • TABLE 3: World Current & Future Analysis for B2B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 4: World 7-Year Perspective for B2B by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 5: World Current & Future Analysis for B2C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 6: World 7-Year Perspective for B2C by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 7: World Current & Future Analysis for Treatment / Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World 7-Year Perspective for Treatment / Care by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027
    • TABLE 9: World Current & Future Analysis for Preventive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 10: World 7-Year Perspective for Preventive by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 11: USA Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 12: USA 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 13: USA Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 14: USA 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • CANADA
    • TABLE 15: Canada Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 16: Canada 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 17: Canada Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 18: Canada 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • JAPAN
    • TABLE 19: Japan Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Japan 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 21: Japan Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 22: Japan 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • CHINA
    • TABLE 23: China Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 24: China 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 25: China Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: China 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • EUROPE
    • TABLE 27: Europe Current & Future Analysis for Digital Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 28: Europe 7-Year Perspective for Digital Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021 & 2027
    • TABLE 29: Europe Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 30: Europe 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 31: Europe Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Europe 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • FRANCE
    • TABLE 33: France Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 34: France 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 35: France Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 36: France 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • GERMANY
    • TABLE 37: Germany Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Germany 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 39: Germany Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 40: Germany 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • ITALY
    • TABLE 41: Italy Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 42: Italy 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 43: Italy Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Italy 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • UNITED KINGDOM
    • TABLE 45: UK Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 46: UK 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 47: UK Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 48: UK 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • REST OF EUROPE
    • TABLE 49: Rest of Europe Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Rest of Europe 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 51: Rest of Europe Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 52: Rest of Europe 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • ASIA-PACIFIC
    • TABLE 53: Asia-Pacific Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 54: Asia-Pacific 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 55: Asia-Pacific Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Asia-Pacific 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027
  • REST OF WORLD
    • TABLE 57: Rest of World Current & Future Analysis for Digital Therapeutics by Sales Channel - B2B and B2C - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 58: Rest of World 7-Year Perspective for Digital Therapeutics by Sales Channel - Percentage Breakdown of Value Revenues for B2B and B2C for the Years 2021 & 2027
    • TABLE 59: Rest of World Current & Future Analysis for Digital Therapeutics by Application - Treatment / Care and Preventive - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 60: Rest of World 7-Year Perspective for Digital Therapeutics by Application - Percentage Breakdown of Value Revenues for Treatment / Care and Preventive for the Years 2021 & 2027

IV. COMPETITION

  • Total Companies Profiled: 108